<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04367688</url>
  </required_header>
  <id_info>
    <org_study_id>MSS325R</org_study_id>
    <nct_id>NCT04367688</nct_id>
  </id_info>
  <brief_title>HIV Pre-exposure Prophylaxis Implementation Hong Kong Study</brief_title>
  <official_title>Delivery of Pre-exposure Prophylaxis to Individuals With High Sexual Risk of HIV Infection in Hong Kong - an Implementation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      While pre-exposure prophylaxis (PrEP) is widely recommended and a number of pilot studies are&#xD;
      on-going worldwide, progress of its implementation in the real world setting has been slow,&#xD;
      especially in Asia. This study aims to develop a service model for PrEP delivery and test its&#xD;
      operability in the real world setting. In this implementation study, 400 individuals with&#xD;
      high sexual risk of HIV infection who fulfil eligibility criteria would be recruited.&#xD;
      Eligible participants would receive one year of daily tenofovir disoproxil fumarate 300mg /&#xD;
      emtricitabine 200mg (TDF/FTC) for free. A client-initiated approach would be adopted,&#xD;
      requiring participants to self-arrange for regular HIV/sexually transmitted infections (STI)&#xD;
      testing. An online system would be developed to facilitate participants to plan for testing&#xD;
      and consultation for accessing PrEP. Questionnaire at baseline and subsequent monthly&#xD;
      follow-up would be administered to assess behaviour, monitor adverse effects and drug&#xD;
      adherence, the latter coupled with the completion of an online diary. Testing of HIV and&#xD;
      creatinine would be performed using point-of-care test or by phlebotomy during clinical&#xD;
      visits. Blood samples would be collected for archiving. Around 40 participants would be&#xD;
      invited to join an in-depth interview in the later part of the study to evaluate the service&#xD;
      model. The main outcome measures are: PrEP service adherence, PrEP drug adherence, prevalence&#xD;
      of drug intolerance, prevalence of unprotected sex in the study period, incidence of HIV and&#xD;
      STI&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>adherence to PrEP service</measure>
    <time_frame>12 months</time_frame>
    <description>attending the PrEP service with prescription and HIV tests regularly in accordance with protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adherence to PrEP regimen</measure>
    <time_frame>12 months</time_frame>
    <description>proportion adherent to daily TDF/FTC</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate 300 mg / emtricitabine 200 mg</intervention_name>
    <description>daily use for PrEP</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with high risk sexual behaviours for HIV transmission who are referred by&#xD;
        government/public service or non-government service in Hong Kong or self-referred for&#xD;
        enrolment in a PrEP program&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Can communicate in written and spoken English or Chinese&#xD;
&#xD;
          -  Is normally resident in Hong Kong&#xD;
&#xD;
          -  Has tested HIV antibody negative in the past 3 months&#xD;
&#xD;
          -  Has more than 1 episode of unprotected sex (especially anal sex) in the preceding 6&#xD;
             months&#xD;
&#xD;
          -  Has any one of the following experiences in the past 6 months: chemsex engagement,&#xD;
             group sex, multiple sex partners, STI diagnosis, having sex partner(s) with HIV+ve&#xD;
             status&#xD;
&#xD;
          -  Is inclined to engage in high risk sexual activities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic HBV infection (HBsAg +ve)&#xD;
&#xD;
          -  Impaired renal function, defined as estimated glomerular filtration rate (eGFR) &lt;&#xD;
             60mL/min/1.73m2&#xD;
&#xD;
          -  Having any form of mental illnesses&#xD;
&#xD;
          -  Inability or refusal to give consent&#xD;
&#xD;
          -  Prisoners or any institutionalised persons&#xD;
&#xD;
          -  Pregnant or planning to get pregnant (for female)&#xD;
&#xD;
          -  Injection drug user&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shui Shan Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Shui-Shan Lee, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>pre-exposure prophylaxis</keyword>
  <keyword>adherence</keyword>
  <keyword>antiretroviral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

